Early diagnosis, prevention and treatment of peritoneal sclerosing syndrome;Diagnóstico precoz, prevención y tratamiento de los síndromes esclerosantes peritoneales

Nefrologia

Volumn 23, Issue SUPPL.3, 2003, Pages 38-43

  Selgas, R ^a,b   Bajo, M A ^a,b   Cirugeda, A ^a,b   del Peso, G ^a,b   Aguilera, A ^a,b   Gil, F ^a,b   Fernandez Perpen A ^a,b   Alvarez V ^a,b   Sanchez Tomero J A ^a,b   Lopez Cabrera M ^a,b   Sanchez Madrid F ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Grupo de Estudios Peritoneales de Madrid del Instituto Reina Sofía   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; REVIEW; SCLEROSIS; SYNDROME;

HUMANS; PERITONEAL DIALYSIS; PERITONEAL DISEASES; SCLEROSIS; SYNDROME;

EID: 18344399243     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Selgas R, Fernández-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jiménez C, Del Peso G, De Álvaro F: Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 23: 64-73, 1994.
2. Rippe B: Pathophysiological description of the ultrastructural changes of the peritoneal membrane during long-term continuous ambulatory peritoneal dialysis. Blood Purif 12: 211- 220, 1994.
3. Selgas R, Bajo MA, Del Peso G, Jiménez C: Preserving the peritoneal dialysis membrane in long-term peritoneal dialysis patients. Seminars Dial 8: 326-332, 1995.
4. Selgas R, Bajo MA, Paiva A, Del Peso G, Díaz C, Aguilera A, Hevia C: Stability of the peritoneal membrane in long-term peritoneal dialysis patients. Adv Ren Replac Ther 5: 168-178, 1998.
5. Krediet R: The peritoneal membrane in chronic peritoneal dialysis patients. Kidney Int 55: 341-356, 1999.
6. Mistry CD, Gokal R, Peers E, and the MIDAS Study Group: a randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 46: 496-503, 1994.
7. Garosi G, Gaggiotti E, Monaci G, Brardi S, Di Paolo N: Biocompatibility of a peritoneal dialysis solution with aminoacids: histological evaluation in the rabbit. Perit Dial Int 18: 610-619, 1998.
8. Jones MR, Gehr TW, Burkart JM, Hamburger RJ, Kraus AP, Piraino B, Hagen T, Ogrinc FG, Wolfson M: Replacement of Aminoacid and protein losses with 1.1% aminoacid peritoneal dialysis solution. Perit Dial Int 18: 210-216, 1998.
9. Selgas R, López-Rivas A, Miranda B, Muñoz J, Riñón C, Borrego F, Molina S, Sánchez-Sicilia: Characterisation of the Mitogenic. Induced Capacity of Peritoneal Effluent on Human and Mice Fibroblastsin culture. Nephrol Dial Transplant 6: 44-50, 1991.
10. Selgas R, Fernández de Castro M, Viguer JM , Burgos E, Bajo MA, Cárcamo C, Vara F: Transformed mesothelial cells in patients on CAPD for medium-to long-term periods. Perit Dial Int 15: 305-311, 1995.
11. Slingeneyer A, Mion C, Mourad G, Ganaud B, Faller B, Beraud JJ: Progressive sclerosing peritonitis: la late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Organs 24: 633-638, 1983
12. Huarte-Loza E, Selgas R y R-Carmona A: Peritoneal membrane failure as a determinant of the CAPD future. An epidemiological, functional an pathological study. Contributions Nephrol 57: 219-229, 1987.
13. Margetts PJ, Kolb M, Galt T: Gene transfer of TGFß to the ratperitoneum: effects on membrane function. J Am Soc Nephrol12: 2029-2039, 2001.
14. Sasuni AA, Zweers MM, Weening J: Expression of Cancer antigen125 by peritoneal mesothelial cells in not influenced by duration of peritoneal dialysis. Perit Dial Int 21: 495-500, 2001.
15. Zweers MM, Waart DR, Smit W, Struijk DG, Krediet RT: Growth factors VEGF and TGF-ß in peritoneal dialysis. J Lab Clin Med 134: 124-32, 1999.
16. Selgas R, Del Peso G, Bajo MA: Levels of vascular endotelial growth factor in peritoneal dialysis effluent. J Nephrol 14: 270-274, 2001.
17. Wang T, Cheng YG, Ye RG, Li SL, Li HQ, Chen YX: Effects of glucose on TGF-ß1 expression in peritoneal mesothelial cells. Adv Perit Dial 11: 7-10, 1995.
18. Yung S, Coles G, Williams J, Davies M: The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 46: 527-533, 1994.
19. Yamamoto I, Izumoteni T, Otoshi T: Morphological studies of mesothelial cells in CAPD effluent and their clinical significance. Am J Kidney Dis 32: 946-952, 1998.
20. Izumotani T, Ishimura E, Yamamoto T: Correlation between peritoneal mesothelial cell citology and peritoneal histopathologywith respect to prognosis on CAPD. Nephron 89: 43-49, 2001.
21. Castro MA, Díaz C, Bajo MA, Sánchez-Cabezudo MJ, Fernández de Castro M, Del Peso G, Martínez ME, Selgas R: Metodología para evaluar la capacidad de crecimiento ex vivo de las células mesoteliales obtenidas directamente del efluente peritoneal. Nefrología 20: 277-283, 2000.
22. Díaz C, Selgas R, Castro MA, Bajo MA, Fernández de CastroM, Molina S, Jiménez C, Ortiz A, Vara F: Ex vivo proliferationof mesothelial cells directly obtained from peritoneal effluent. Its relation with peritoneal antecedents andfunctional parameters. Adv Perit Dial 14: 19-24, 1998.
23. Yáñez-Mo M, Lara-Dezzi E, Selgas R: Peritoneal dialysis induces an epithelial-mesenchimal transition of mesothelial cell. N Eng J Med (in press).
24. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C: Toward better dialysis compatibility: advances in the biochemistryand pathophysiology of the peritoneal membrane. Kidney Int 61: 375-386, 2002.
25. Selgas R, Del Peso G, Bajo MA: Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis. Perit Dial Int 20: 798-801, 2000.
26. De Alvaro F, Castro MJ, Dapena F, Bajo MA, Fdez.-Reyes MJ, Romero JR, Jiménez C, Miranda B, Selgas R: Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 9: 56-61, 1993.
27. Ogawa T, Hayashi T, Yorioka N: Hexamethylene bisacetamide protects peritoneal mesothelial cell from glucose. Kidney Int 60: 996-1008, 2001.
28. Gunal AI, Celiker H, Akpolat N y cols.: By reducing production of vascular endotelial growth factor Octeotride improves the peritoneal vascular alterations induced by hypertonic peritoneal diálisis solution. Perit Dial Int 22: 301-306, 2002.
29. Imai H, Nakamoto H, Ishida Y: Glucocorticoid restores the deterioration of water transport in the peritoneum through increment in Aquaporin. Adv Perit Dial 16: 297-302, 2000.
30. Ogata S, Yorioka S: Effect of prednisolone on increased expression of laminin by human peritoneal mesothelial cells cultured with high glucose. Adv Perit Dial 17: 2-4, 2001.
31. Kawanishi H: Surgical treatment for Encapsulating Peritoneal Sclerosis. Adv Perit Dial 18: 139-143, 2002
32. Morishi M, Kawanishi H, Kawai T, Syunsake T, Hirai T, Shishida M, Watanabe H, Takanishi N: Preservation of peritonealcatheter for prevention of encapsulating peritoneal sclerosis.Adv Perit Dial 18: 149-153, 2002.
33. Chau D, Mancoll JS, Lee S, Zhao J, Phillips L, Gittes G, Longaker MT: Tamoxifen downregulates TGF-ß production in keloid fibroblasts. Ann Plast Surg 40: 490-493, 1998.